Cooper (NYSE: COO )
, or more formally "The Cooper Companies" is a sort of odd duck in the
med-tech world. It's fairly well-respected by eye care rivals like Johnson & Johnson (NYSE: JNJ ) and Novartis (NYSE: NVS )
; it has done well in the market (up more than 280% over five years and
about 55% over the past 12 months); and it's well-followed and
well-owned on the Street.
Even so, it doesn't generate much pizzazz with individual
investors, and there's not much coverage of it out there. Some of that
may be due to valuation -- as Cooper rarely trades at a multiple I'd
call cheap -- but this is a story likely to feature strong market share
gains and meaningful margin/free cash flow leverage, and those tend to
be the stocks that outperform.
Please read more of this article at The Motley Fool:
http://www.fool.com/investing/general/2013/09/06/cooper-leveraging-share-gains-for-eye-opening-grow.aspx
No comments:
Post a Comment